Please use a PC Browser to access Register-Tadawul
Get It
NeuroSense Therapeutics shares are trading lower. The company announced the availability of additional long-term survival data from its PARADIGM Phase 2b clinical trial evaluating PrimeC.
Neurosense Therapeutics Ltd. NRSN | 0.87 | +1.38% |
